Sino Biopharmaceutical's Phase-3 Trial of Breast Cancer Drug Reaches Primary Endpoint
Sino Biopharmaceutical's Phase-3 Trial of Breast Cancer Drug Reaches Primary Endpoint
s bpharm b2502的乳腺癌药物三期试验达到主要终点
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册